

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CRESO PHARMA LIMITED
ABN	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Adam Blumenthal
Date of last notice	23 July 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C> (an entity controlled by Mr Blumenthal)
Date of change	21 August 2018
No. of securities held prior to change	<p>Direct (Adam Blumenthal)</p> <p>1 fully paid ordinary share (subject to escrow until 20 October 2018)</p> <p>Indirect (Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C>)</p> <p>4,000,000 fully paid ordinary shares (subject to escrow until 20 October 2018).</p> <p>1,500,000 fully paid ordinary shares</p> <p>750,000 performance rights subject to vesting conditions (issued 14 December 2015) (subject to escrow until 20 October 2018)</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Unlisted Options (<i>exercisable at \$0.80 on or before 21 August 2020</i>)
Number acquired	2,750,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.05 per Option
No. of securities held after change	<p>Direct (Adam Blumenthal)</p> <p>1 fully paid ordinary share (<i>subject to escrow until 20 October 2018</i>)</p> <p>Indirect (Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C>)</p> <p>4,000,000 fully paid ordinary shares (<i>subject to escrow until 20 October 2018</i>).</p> <p>1,500,000 fully paid ordinary shares</p> <p>750,000 performance rights subject to vesting conditions (<i>issued 14 December 2015</i>) (<i>subject to escrow until 20 October 2018</i>)</p> <p>2,750,000 Unlisted Options (<i>exercisable at \$0.80 on or before 21 August 2020</i>)</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Take up of entitlement under the Company's Options Entitlement Issue pursuant to Prospectus lodged with ASX on 25 July 2018.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CRESO PHARMA LIMITED
ABN	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Ellingford
Date of last notice	30 July 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	21 August 2018
No. of securities held prior to change	1,000,000 fully paid ordinary shares (subject to 24 months escrow) 250,000 performance rights subject to vesting conditions (subject to escrow to 20 October 2018) 100,000 performance rights subject to vesting conditions (issued 27 July 2017 following grant of shareholder approval obtained on this date) 100,000 fully paid ordinary shares
Class	Unlisted Options (exercisable at \$0.80 on or before 21 August 2020)

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number acquired	550,000
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.05 per Option
No. of securities held after change	1,000,000 fully paid ordinary shares (<i>subject to 24 months escrow</i>) 250,000 performance rights subject to vesting conditions (<i>subject to escrow to 20 October 2018</i>) 100,000 performance rights subject to vesting conditions (<i>issued 27 July 2017 following grant of shareholder approval obtained on this date</i>) 100,000 fully paid ordinary shares 550,000 Unlisted Options (<i>exercisable at \$0.80 on or before 21 August 2020</i>)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Take up of entitlement under the Company's Options Entitlement Issue pursuant to Prospectus lodged with ASX on 25 July 2018.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CRESO PHARMA LIMITED
ABN	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Boaz Wachtel
Date of last notice	31 March 2017 & 27 July 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	International Water and Energy Savers Ltd (an entity controlled by Mr Wachtel)
Date of change	21 August 2018
No. of securities held prior to change	Indirect (International Water and Energy Savers Ltd) 6,800,000 fully paid ordinary shares (subject to 24 months escrow) 1,500,000 performance rights subject to vesting conditions. 1,600,000 performance rights subject to vesting conditions (issued 27 July 2017 following grant of shareholder approval obtained on this date)
Class	Unlisted Options (exercisable at \$0.80 on or before 21 August 2020)

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number acquired	3,000,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.05 per Option
No. of securities held after change	<p>Indirect (International Water and Energy Savers Ltd)</p> <p>6,800,000 fully paid ordinary shares (subject to 24 months escrow)</p> <p>1,500,000 performance rights subject to vesting conditions.</p> <p>1,600,000 performance rights subject to vesting conditions (issued 27 July 2017 following grant of shareholder approval obtained on this date)</p> <p>3,000,000 Unlisted Options (exercisable at \$0.80 on or before 21 August 2020)</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Take up of entitlement under the Company's Options Entitlement Issue pursuant to Prospectus lodged with ASX on 25 July 2018.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CRESO PHARMA LIMITED
ABN	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Miri Halperin Wernli
Date of last notice	31 March 2017 & 27 July 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	21 August 2018
No. of securities held prior to change	8,250,000 fully paid ordinary shares <i>(subject to 24 months escrow)</i> 1,750,000 performance rights subject to vesting conditions <i>(subject to escrow to 20 October 2018)</i> 2,500,000 performance rights subject to vesting conditions <i>(issued 27 July 2017 following grant of shareholder approval obtained on this date)</i>
Class	Unlisted Options <i>(exercisable at \$0.80 on or before 21 August 2020)</i>

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number acquired	4,072,950
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.05 per Option
No. of securities held after change	<p>8,250,000 fully paid ordinary shares (subject to 24 months escrow)</p> <p>1,750,000 performance rights subject to vesting conditions (subject to escrow to 20 October 2018)</p> <p>2,500,000 performance rights subject to vesting conditions (issued 27 July 2017 following grant of shareholder approval obtained on this date)</p> <p>4,072,950 Unlisted Options (exercisable at \$0.80 on or before 21 August 2020)</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Take up of entitlement under the Company's Options Entitlement Issue pursuant to Prospectus lodged with ASX on 25 July 2018.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.